Effect of Rutin on Inflammation Pathways in Ulcerative Colitis Patients

Benha University60 enrolled

Overview

This study evaluates the therapeutic role of Rutin (a plant-derived flavonoid) in reducing the severity of Ulcerative Colitis (UC). The study investigates whether Rutin can decrease intestinal inflammation and improve clinical symptoms by inhibiting the NLRP3 inflammasome signaling pathway, which is activated by oxidative stress in the colon.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

SINGLE

Enrollment

Conditions

Ulcerative Colitis

Interventions

Rutin 500 MG Oral TabletDRUG

Oral capsules twice daily for 30 days

Fecal CalprotectinDIAGNOSTIC_TEST

Sample collection only for baseline comparison.

PlaceboDRUG

Placebo tablets for 30 days

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of UC confirmed by endoscopy/histology. * Age 18 to 65 years. Exclusion Criteria: * Pregnancy or breastfeeding. * Known hypersensitivity to Rutin. * Presence of other serious systemic diseases (e.g., malignancy, severe hepatic or renal failure).

Locations (1)

Benha Faculty of Medicine

Banhā, Al Qalyoubia, Egypt

Outcomes

Primary Outcomes

Success Rate of Clinical Improvement

The percentage of participants who achieve clinical improvement at the end of the treatment period. Clinical improvement is defined as reaching a score of 5 or less on the Simple Clinical Colitis Activity Index (SCCAI).

Time frame: Day 30 (End of treatment)

Secondary Outcomes

Change in Fecal Calprotectin Levels

The concentration of Fecal Calprotectin measured in stool samples to quantify the reduction in intestinal inflammation.

Time frame: Baseline and Day 30

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.